Drug Discovery and the Impact of mAbs

In another significant mAb collaboration. Fibrocor Therapeutics agreed a research and development (R&D) collaboration with the McQuade Center for Strategic Research and Development (MSRD) in March 2024 to advance its Alpon Syndrome programme. Phase I clinical trials of mAb FIB918 are targeted to start in late 2025. William Newsome. CEO President of Fibroccr comments: “This collaboration with the experienced team at MSRO. coupled with research funding, represents hope and potential for individuals grappling with Alport Syndrome worldwide. FIB918 has the potential to deliver a significant advancement in the treatment of patients afflicted by this debilitating disease. where current options are limited.”

Read the attached e-book

DDW eBook_Drug Discovery and the Impact of mAbs_April2024